Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 260-263

  Hoskin, P J ^a   Saunders, M I ^a   Phillips, H ^a   Cladd, H ^a   Powell, M E B ^a   Goodchild, K ^a   Stratford, M R ^a   Rojas, A ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Carbogen; Hypoxia; Nicotinamide

Indexed keywords

CARBOGEN; NICOTINAMIDE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DEFECATION; DRUG BLOOD LEVEL; HUMAN; HYPOXIA; INHALATIONAL DRUG ADMINISTRATION; INTESTINE FUNCTION; MORBIDITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030914416     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.372     Document Type: Article

References (25)

1. Cade IS, McEwan JB, Dische S, Saunders MI, Watson ER, Halnan KE, Wiernik G, Perrins DJD and Sutherland I (1978) Hyperbaric oxygen and radiotherapy: a Medieal Research Council trial in carcinoma of the bladder. B J Radiol 51: 876-878
2. Chaplin DJ, Olive PL and Durand RE (1987) Intermittent blood flow in a murine tumour: radiobiological effects. Cancer Res 47: 597-601
3. Dische S, Warburton MF, Jones D and Lartigau E (1989) The recording of morbidity related to radiotherapy. Radiother Oncol 16: 103-108
4. Dische S (1991) What have we learnt from hyperbaric oxygen? Radiother Oncol 20(suppl. 1): 71-74
5. Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol. 7: 299-310
6. Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B (1985) Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol 4: 197-203
7. Falk SJ, Ward R and Bleemen NM (1995) The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised PO, histography. Br J Cancer 66: 912-924
8. Hill SA and Chaplin DJ (1995) The effect of nicotinamide on microregional blood flow within tumours assessed using laser doppler probes. lnt J Rad Oncol Biol Phys 16: 931-934
9. Hope-Stone HF, Blandy JP, Oliver RTD, England H (1981) Radical radiotherapy and salvage cystectomy in the treatment of invasive carcinoma of the bladder. In Bladder Cancer: Principles of Combination Therapy. Oliver RTD, Hendry WF and Bloom HJG (Eds), pp. 127-136, Butterworths: London
10. Horsman MR, Brown JM, Hirst VK, Lemmon MJ, Wood PJ, Overgaard J (1988) Mechanism of action of the selective tumour radiosensitiser nicotinamide. Int J Rad Oncol Biol Phys 15: 658-690
11. Hoskin PJ, Stratford MRL, Saunders MI, Hall DW, Dennis M, Rojas AM (1995) Administration of nicotinamide during CHART: pharmacokinetics dose escalation and clinical toxicity. Int J Rad Oncol Biol Phys 32: 1111 -1119
12. Kaanders JHAM, Stratford MRL, Liefers J, Dennis MF, Rojas A, van Daal WAJ, van der Kogel AJ (1997) Administration of nicotinamide during a five to seven week course of irradiation: pharmacokinetics and tolerance. Radiother Oncol 42: (in press)
13. Kelleher DK, Vaupel PW (1993) Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumours, Int J Rad Oncol Biol Phys 26: 95-102
14. Keresteci AG, Rider WD (1978) Use of orthobaric oxygen in the radiotherapy of bladder tumours. Can J Surg 16: 127-129
15. Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A (1991) A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother Oncol 22: 81-91
16. Rew DA, Thomas DJ, Coptcoat M, Wilson GD (1991) Measurement of in vivo urological tumour cell kinetics using multiparameter flow cytometry. B J Urol 68: 44-48
17. Rojas A (1991) Radiosensitisation with normobaric oxygen and carbogen. Int J Rad Oncol Biol Phys 20: 65-70
18. Rojas A (1992) ARCON: Accelerated radiotherapy with carbogen and nicotinamide. B J Radiol 24: 174-178
19. Rojas A, Johns H, Fiat RP (1993) Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimes? Int J Rad Oncol Biol Phys 27: 1101-1105
20. Rojas A, Hirst VK, Calvert A, Johns H (1996) Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy, Int J Rad Oncol Biol Phys 34: 357-365
21. Rubin P, Hanley J, Keys HM, Marcial V, Brady L (1979) Carbogen breathing during radiation therapy. Int J Rad Oncol Biol Phys 5: 1963-1970
22. Saunders MI, Hoskin PJ, Pigott K, Powell MEB, Rojas AM, Stratford M (1996) A phase 1/11 study of ARCON (accelerated radiotherapy, with carbogen and nicotinamide) in locally advanced head and neck cancer. B J Cancer 74 (suppl. XXVIII): 20
23. Siemann DW, Horsman MR, Chaplin DJ (1994) The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol 31: 117-122
24. Stratford M, Dennis M, Hoskin PJ, Saunders MI, Hodgkiss R, Rojas A (1996) Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol 35: 213-219
25. Trotter MJ, Chaplin DJ, Durand RE and Olive PL (1989) The use of fluorescent probes to identify regions of transient perfusion in murine tumors, Int J Rad Oncol Biol Phys 16: 931-934